GlassScriptPhysician profile
Joseph Herman
NPI 1841984820
$1,302.79
in general payments reported to CMS, 2019-2025
18 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $48.36 · 2024: $666 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $295.80 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.58 | 2024-2025 | Xifaxan, Trulance |
| Intra-Sana Laboratories | $180.48 | 2024-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Exact Sciences Corporation | $106.02 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $78.45 | 2024-2025 | Zepbound, Mounjaro, Kisunla |
| Viiv Healthcare Company | $67.97 | 2025 | Apretude |
| Medtronic, INC. | $51.04 | 2024 | Minimed 780g |
| Glaxosmithkline, LLC. | $49.95 | 2025 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $41.26 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $39.48 | 2025 | Rexulti |
| Pfizer INC. | $34.24 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $30.96 | 2024-2025 | Breztri, Fasenra |
| Axsome Therapeutics, INC. | $30.74 | 2025 | Auvelity |
| Gilead Sciences, INC. | $20.20 | 2025 | |
| Organon LLC | $17.95 | 2025 | Nexplanon |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.89 | 2024 | M-M-R II, Vaxelis, Gardasil 9 |
| Amgen INC. | $15.73 | 2025 | Repatha, Otezla |
| Xeris Pharmaceuticals, INC. | $14.05 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.